Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

SEC Filings

SEC Filings

Form Description Filing date View
8-K

Report of unscheduled material events or corporate event

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

View HTML
424B4

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3

View HTML
CT ORDER

CT ORDER

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML

Copyright Morningstar



Copyright 2018 - Stemline Therapeutics, Inc. All rights reserved